ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,892.67
0.35%
Dow Jones
42,526.05
0.47%
US Dollar vs MXN
20.3363
-0.28%
Brent Oil
72.455
-0.38%
Bitcoin
96,503.22
-3.56%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mirum Pharmaceuticals Inc (MIRM)

  7. Mirum Pharmaceuticals Inc (MIRM) Noticias

MIRM

Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MIRM
FechaHoraFuenteTítuloSímboloCompañía
10/12/202417:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
15/11/202416:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRMMirum Pharmaceuticals Inc
14/11/202407:00Business WireMirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202410:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202407:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202407:00Business WireMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
07/11/202415:30Business WireMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:MIRMMirum Pharmaceuticals Inc
04/11/202415:30Business WireMirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
31/10/202407:30Business WireMirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
10/10/202407:30Business WireVolixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202415:01Business WireMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
31/07/202415:30Business WireMirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
25/07/202407:30Business WireMirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202415:46Business WireApprobation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202415:20Business WireLIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassenNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202407:30Business WireMirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
28/06/202407:30Business WireMirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTXNASDAQ:MIRMMirum Pharmaceuticals Inc
17/06/202407:00Business WireMirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesNASDAQ:MIRMMirum Pharmaceuticals Inc
16/06/202416:00Business WireMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
06/06/202423:04Business WireLangfristige Daten aus den LIVMARLI-Studien von Mirum bei ALGS und PFIC auf dem EASL-Kongress vorgestelltNASDAQ:MIRMMirum Pharmaceuticals Inc
06/06/202423:04Business WireLes données à long terme des études LIVMARLI de Mirum sur l’ALGS et la PFIC présentées au congrès de l’EASLNASDAQ:MIRMMirum Pharmaceuticals Inc
06/06/202408:30Business WireLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL CongressNASDAQ:MIRMMirum Pharmaceuticals Inc
05/06/202415:05Business WireMirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202416:02Business WireMirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei MonatenNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202412:12Business WireMirum Pharmaceuticals annonce un avis favorable du CHMP pour la solution orale LIVMARLI® (maralixibat) dans le traitement des patients atteints de CIFP âgés de trois mois et plusNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202407:30Business WireMirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
29/05/202407:30Business WireLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL CongressNASDAQ:MIRMMirum Pharmaceuticals Inc
18/05/202406:00Business WireMirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
08/05/202415:02Business WireMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRM

Su Consulta Reciente

BIT
S24554
SG ISSUER
BIT
I10447
IT0005615924 20250602 13.5
BIT
AT1D
Invesco AT1 Capital Bond...
EU
BE0002478536
Infrax CVBA 14/29
BIT
I08974
Intesa Sanpaolo
BIT
S29061
Societe Generale Effekten
BIT
SGLE
Invesco Physical Gold Eu...
BIT
ENWD
Ishares MSCI World ESG E...
BIT
AFRN
Amundi EUR Floating Rate...
BIT
USE3
ETFS 3x Short USD Long EUR
LSE
RJ24
Roy.bk.can.42
BOV
BEEF3
MINERVA ON
BIT
SNXIS5
Societe Generale Effekten
BIT
I08645
Intesa Sanpaolo
BIT
C13
Exchange Traded
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados